Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, et al. NCCN Guidelines(R) Insights: Multiple Myeloma, Version 3.2022. J Natl Compr Canc Netw. 2022;20:8–19.

Article  PubMed  Google Scholar 

Rodriguez-Otero P, Paiva B, San-Miguel JF. Roadmap to cure multiple myeloma. Cancer Treat Rev. 2021;100:102284.

Article  PubMed  Google Scholar 

Zaleta AK, Miller MF, Olson JS, Yuen EYN, LeBlanc TW, Cole CE, et al. Symptom Burden, Perceived Control, and Quality of Life Among Patients Living With Multiple Myeloma. J Natl Compr Canc Netw. 2020;18:1087–95.

Article  PubMed  Google Scholar 

Terpos E, Ntanasis-Stathopoulos I, Roussou M, Kanellias N, Fotiou D, Migkou M, et al. Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period. Ann Hematol. 2020;99:1257–64.

Article  CAS  PubMed  Google Scholar 

Oliver-Caldes A, Soler-Perromat JC, Lozano E, Moreno D, Bataller A, Mozas P, et al. Long-Term Responders After Autologous Stem Cell Transplantation in Multiple Myeloma. Front Oncol. 2022;12:936993.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paquin A, Visram A, Kumar SK, Gertz MA, Cantwell H, Buadi FK, et al. Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma. Blood Cancer J. 2020;10:87.

Article  PubMed  PubMed Central  Google Scholar 

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e46.

Article  PubMed  Google Scholar 

Bryant C, Suen H, Brown R, Yang S, Favaloro J, Aklilu E, et al. Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer J. 2013;3:e148.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arteche-Lopez A, Kreutzman A, Alegre A, Sanz Martin P, Aguado B, Gonzalez-Pardo M, et al. Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication. Bone Marrow Transpl. 2017;52:832–8.

Article  CAS  Google Scholar 

Pessoa de Magalhaes RJ, Vidriales MB, Paiva B, Fernandez-Gimenez C, Garcia-Sanz R, Mateos MV, et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica. 2013;98:79–86.

Article  PubMed  Google Scholar 

Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1782–91.

Article  CAS  PubMed  Google Scholar 

McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. J Clin Oncol. 2017;35:3279–89.

Article  CAS  PubMed  Google Scholar 

Pasvolsky O, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, et al. Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience. Am J Hematol. 2023;98:1571–8.

Article  CAS  PubMed  Google Scholar 

Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014;15:333–42.

Article  CAS  PubMed  Google Scholar 

de Tute RM, Pawlyn C, Cairns DA, Davies FE, Menzies T, Rawstron A, et al. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. J Clin Oncol. 2022;40:2889–900.

Article  PubMed  Google Scholar 

Diamond B, Korde N, Lesokhin AM, Smith EL, Shah U, Mailankody S, et al. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2021;8:e422–e32.

Article  CAS  PubMed  Google Scholar 

Gay F, Roeloffzen W, Dimopoulos MA, Rosiñol L, van der Klift M, Mina R, et al. Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients. Blood. 2023;142:4.

Article  Google Scholar 

Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023;10:e825–e37.

Article  CAS  PubMed  Google Scholar 

Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398:314–24.

Article  CAS  PubMed  Google Scholar 

Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022;387:495–505.

Article  CAS  PubMed  Google Scholar 

Munshi NC, Anderson LD Jr., Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384:705–16.

Article  CAS  PubMed  Google Scholar 

Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022;387:132–47.

Article  CAS  PubMed  Google Scholar 

Pasvolsky O, Marcoux C, Dai J, Milton DR, Tanner MR, Syed N, et al. Trends in Outcomes over Three Decades after Upfront Autologous Stem Cell Transplant for Multiple Myeloma at MD Anderson Cancer Center. Blood. 2023;142:4962.

Article  Google Scholar 

Harousseau JL, Avet-Loiseau H, Attal M, Charbonnel C, Garban F, Hulin C, et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. J Clin Oncol. 2009;27:5720–6.

Article  CAS  PubMed  Google Scholar 

Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112:4017–23.

Article  CAS  PubMed  Google Scholar 

Pasvolsky O, Pasyar S, Bassett RL, Khan HN, Tanner MR, Bashir Q, et al. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer. 2024;130:1663–72.